APA (7th ed.) Citation

X, W., AM, P., X, X., SJ, C., CL, B., V, P., . . . T, C. (2024). Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims. JMIR diabetes, 9, e58137. https://doi.org/10.2196/58137

Chicago Style (17th ed.) Citation

X, Wang, Plantinga AM, Xiong X, Cromer SJ, Bonzel CL, Panickan V, Duan R, Hou J, and Cai T. "Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims." JMIR Diabetes 9 (2024): e58137. https://doi.org/10.2196/58137.

MLA (9th ed.) Citation

X, Wang, et al. "Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims." JMIR Diabetes, vol. 9, 2024, p. e58137, https://doi.org/10.2196/58137.